Click here for slides on this topic


Lifestyle modifications

Nonpharmacologic measures that contribute to a healthier lifestyle and may reduce an individual's risk for, or prevent the development of, medical conditions, including type 2 diabetes, hypertension, dyslipidemia, obesity, and cardiovascular disease (CVD).


The following content matched the glossary term: Lifestyle modifications

AHA ADA prevention of CVD in T2D - Lifestyle Management

Top

Summary of lifestyle management recommendations from the AHA ADA cardiovascular disease (CVD) prevention in type 2 diabetes guidelines.

AACE 2015 guidelines Cardiovascular Disease Management

Top

Summary of recommendations for managing cardiovascular disease (CVD), including dyslipidemia and hypertension, from the 2015 AACE diabetes guidelines 

AACE 2015 guidelines Obesity Management

Top

Summary of the obesity treatment algorithm, including pharmacologic therapy and bariatric surgery, from the 2015 AACE diabetes guidelines 

AACE 2015 guidelines Lifestyle Changes

Top

Summary of recommendations for lifestyle modifications to treat diabetes from the 2015 AACE guidelines  

Endocrine Society obesity clinical practice guideline

Top

Summary of guidelines for managing obesity with pharmacologic therapy from the Endocrine Society.

NDEI.org Expert Commentary Silvio E. Inzucchi MD on the Impact of Lifestyle Interventions on Healthcare Services

Top

EXPERT COMMENTARY Expert blog post from Silvio E. Inzucchi, MD: "While intensive lifestyle changes to promote weight loss may not have any measurable effects on hard cardiovascular outcomes, with the adoption of a healthier lifestyle, healthcare costs can be substantially reduced."

Impact of an intensive lifestyle intervention on use and cost of medical services among overweight and obese adults with type 2 diabetes

Top

Exclusive! Expert diabetes blog post from Silvio E. Inzucchi, MD. Espeland MA, Glick HA, Bertoni A, et al; for the Look AHEAD Research Group. Impact of an intensive lifestyle intervention on use and cost of medical services among overweight and obese adults with type 2 diabetes: The Action for Health in Diabetes. Diabetes Care. 2014;37:2548-2566.

Supporting a Family Member or Friend With Type 2 Diabetes

Top

Patient education handout that provides tips for offering support to a family member, friend, or loved one with type 2 diabetes.

Managing the Patient With Type 2 Diabetes and Heart Failure

Top

.style1 FONT FAMILY Arial, Helvetica, sans serif COLOR #004685

Endocrine Society Guideline on Diabetes and Pregnancy - Glycemic Targets & Glucose Management

Top

Diabetes Management Guidelines Endocrine Society Guideline on Diabetes and Pregnancy   Source Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013 98(11) 4227 4249. Available here.Refer to

1 2 3 4 5 6 Next 

Slide Library Results

Search Results for: Lifestyle modifications Slides Found: 30
ACP: Recommendations for Oral Pharmacologic Therapy for Type 2 Diabetes
ACP: Considerations for Oral Pharmacologic Therapy in Type 2 Diabetes
BLOOM-DM: Design
Look AHEAD: 1-Year Interim Results
Look AHEAD at 1 Year: Interventions
Look AHEAD at 1 Year: Change in Body Weight
Look AHEAD at 1 Year: Change in Fitness Levels
Look AHEAD at 1 Year: Additional Results
Look AHEAD: Design
Look AHEAD: Lifestyle Interventions
Look AHEAD: 4-Year Data Analysis
Look AHEAD at 4 Years: Weight Reduction
Look AHEAD at 4 Years: Percent Weight Reduction and Gain
Look AHEAD at 4 Years: Weight Reduction By Subgroup, Insulin Use
Look AHEAD at 4 Years: Weight Maintenance
Type 2 Diabetes Remission in Look AHEAD
Look AHEAD: Partial or Complete Type 2 Diabetes Remission
Look AHEAD: Return to Clinical Diabetes Status By Year
Look AHEAD: Continuous, Sustained Type 2 Diabetes Remission
Look AHEAD: No Reduction in CV Events with Lifestyle Changes
Look AHEAD: No Reduction in Secondary CV Outcomes with Lifestyle Changes
Look AHEAD: Greater Weight Reduction with Lifestyle Changes
Look AHEAD: Lifestyle Changes Improve Glycemic Control, CV Risk Factors
Look AHEAD: Primary Outcome, Participant Characteristics
Long-Term Obesity Medications: At Least 5% Weight Loss After 1 Year
SEQUEL Subanalysis: Percent Weight Loss from Baseline at Wk 108 Primary Endpoint
SEQUEL Subanalysis: Annualized Incidence of Type 2 Diabetes at Wk 108
SEQUEL Subanalysis: Reduction of Type 2 Diabetes Incidence Related to Greater Weight Loss
SEQUEL Subanalysis: Design
Phentermine + Topiramate A1C Targets Obese Subjects With Type 2 Diabetes | NDEI